Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Transplantation Proceedings
Suparno ChakrabartiHerman Waldmann

Abstract

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo following reduced-intensity conditioning and unrelated donor conventional transplantation was associated with durable engraftment and significant reduction in graft-versus-host disease (GVHD) but at the cost of impaired immune reconstitution and increased infectious complications. Alemtuzumab exposure in vitro was associated with durable engraftment and reduced GVHD following conventional transplants without affecting immune recovery to the same extent. Improved results were obtained following a further reduction in the alemtuzumab dose in vitro from 20 mg to 10 mg. Subsequent pharmacokinetic studies on alemtuzumab demonstrated that the antibody persisted at a higher concentration at the time of transplant and for at least 2 months thereafter when used in vivo compared to persistence for less than 30 days when used at 20 mg in vitro. In this context; an antibody with a shorter half-life, like the original rat CD52 antibody Campath-1G, w...Continue Reading

References

Mar 24, 1988·Nature·L RiechmannG Winter
Aug 16, 2002·Medical Oncology·Geoff Hale

❮ Previous
Next ❯

Citations

Sep 17, 2013·Bone Marrow Transplantation·A MarekUNKNOWN Swiss Blood Stem Cell Transplantation
Oct 23, 2008·Expert Review of Hematology·John Koreth, Joseph H Antin
Jan 26, 2007·Expert Opinion on Biological Therapy·Lakshmanan Krishnamurti
Mar 16, 2007·British Journal of Haematology·Edward S Morris, Geoffrey R Hill
May 25, 2006·Seminars in Oncology·Sergio Giralt
Feb 2, 2010·Hematology/oncology and Stem Cell Therapy·Lucille WoodPeter Jacobs
Jan 27, 2017·Science Translational Medicine·Waseem QasimPaul Veys
Jul 5, 2017·Expert Review of Hematology·Christos Georgiadis, Waseem Qasim
Jan 12, 2019·American Journal of Hematology·Waseem Qasim
Jan 21, 2006·Journal of Clinical Apheresis·Sang Kyun SohnDong Hwan Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.